A cluster of antibody-drug conjugate (ADC) combination trials and FDA decisions is converging on 2026–2027, creating a compressed binary-event calendar for oncology investors.
Crescent Biopharma's CR-001, a PD-1×VEGF bispecific antibody, is enrolling in the ASCEND trial. Paired ADC combination studies are planned alongside ASCEND to broaden coverage across multiple solid tumor types, with initial data expected in Q1 2027.1
SystImmune is advancing izalontamab brengitecan through clinical development. The company's data, presented at ASCO 2026, drew on its capacity to "rapidly translate innovative science into differentiated therapies for patients with high unmet need worldwide," per Chief Medical Officer Jie D'Elia.2
Exelixis is presenting multiple datasets at ASCO 2026. CMO Dana T. Aftab described the collection as a testament to "improving the standards of care for patients with cancer."3
China partnerships are accelerating pipeline timelines. HUTCHMED and Innovent secured NMPA approval for ELUNATE (fruquintinib) combined with TYVYT (sintilimab) in locally advanced or metastatic renal cell carcinoma.4 Professor Dingwei Ye called the approval a demonstration of the combination's "potential to address the pressing medical needs" of RCC patients.4 The decision validates precision combination regimens beyond U.S. markets and adds a milestone-payment angle for China-partnered developers.
Aktis Oncology is advancing targeted alpha therapy, adding a fourth modality — radiopharmaceuticals — alongside ADCs, bispecifics, and checkpoint inhibitors. The broadening modality mix expands addressable combination pairings for platform companies.
For investors, the structural argument is straightforward: single-agent ADCs face ceiling effects in heavily pre-treated populations. Pairing them with PD-1×VEGF bispecifics or radiopharmaceutical payloads targets resistance pathways that monotherapy cannot reach. Companies demonstrating combination synergy in Phase 1/2 front-line settings carry the strongest re-rating potential.
The 2026–2027 regulatory window compresses that risk. A failed combination readout reprices the entire platform. A positive one — particularly in a front-line setting or a large indication — can trigger swift market re-rating before broader Phase 3 data arrives. Portfolio managers holding multiple names in this cluster face correlated event risk heading into the second half of 2026.
